Posted on by admin

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca
The Key Leptomeningeal Metastases Companies in the market include – Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca, and others.

 

The Leptomeningeal Metastases market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Leptomeningeal Metastases pipeline products will significantly revolutionize the Leptomeningeal Metastases market dynamics. 

 

DelveInsight’s “Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Leptomeningeal Metastases market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Leptomeningeal Metastases Market Insights

 

Some of the key facts of the Leptomeningeal Metastases Market Report:  

  • The Leptomeningeal Metastases market size was valued at USD 1,300 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) 

  • In Febuary 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology firm focused on oncology, announced the early conclusion of a significant two-part Phase I trial due to positive safety results and encouraging clinical responses observed thus far. This investigator-initiated study assessed the use of paxalisib, an oral dual inhibitor of PI3K/mTOR, in conjunction with radiation therapy for treating patients with brain metastases from solid tumors that have PI3K pathway mutations.

  • In 2023, the United States represented around 36% of the total incident cases across various cancer types.

  • In 2023, the United States reported the highest number of diagnosed cases of leptomeningeal metastases, totaling around 122,000. This figure underscores a substantial disease burden and emphasizes the need for improved diagnostic, treatment, and support strategies.

  • In 2023, Japan represented about 20% of the diagnosed cases of leptomeningeal metastases.

  • In 2023, Germany recorded approximately 7,800 cases of leptomeningeal metastases related to breast cancer and around 10,000 cases connected to melanoma.

  • In 2023, Germany represented approximately 30% of the Leptomeningeal Metastases treatment market among the EU4 and the UK, while the UK accounted for about 20%. This share is anticipated to grow at a significant compound annual growth rate (CAGR).

  • Key Leptomeningeal Metastases Companies: Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca, and others

  • Key Leptomeningeal Metastases Therapies: 177Lu-DTPA-O Mburtamab Radioimmunotherapy, Rhenium-186 NanoLiposome, ANG1005, and others

  • Leptomeningeal metastasis is considered the third most common metastatic complication involving the central nervous system (CNS) 

 

Leptomeningeal Metastases Overview

Leptomeningeal metastases (LM), also known as carcinomatous meningitis, refers to the spread of malignant cells through the CSF space. These cells can originate from primary CNS tumors (e.g. drop metastases), as well as from distant tumors that have metastasized via hematogenous spread.

 

Get a Free sample for the Leptomeningeal Metastases Market Report:

https://www.delveinsight.com/report-store/leptomeningeal-metastases-market

 

Leptomeningeal Metastases Epidemiology Segmentation:

The Leptomeningeal Metastases market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Leptomeningeal Metastases

  • Prevalent Cases of Leptomeningeal Metastases by severity

  • Gender-specific Prevalence of Leptomeningeal Metastases

  • Diagnosed Cases of Episodic and Chronic Leptomeningeal Metastases 

 

Download the report to understand which factors are driving Leptomeningeal Metastases epidemiology trends @ Leptomeningeal Metastases Epidemiological Insights

 

Leptomeningeal Metastases Market Drivers

  • Technological advancements 

  • Robust pipeline of emerging assets 

  • High incidence of Leptomeningeal Metastases

 

Leptomeningeal Metastases Therapies and Key Companies

  • 177Lu-DTPA-O Mburtamab Radioimmunotherapy: Y-mAbs Therapeutics

  • Rhenium-186 NanoLiposome: Plus Therapeutics

  • ANG1005: AngioChem

 

Leptomeningeal Metastases Market Barriers

  • Negative impact on quality of life 

  • Limited R&D 

  • High Leptomeningeal Metastases treatment cost

 

Discover more about therapies set to grab major Leptomeningeal Metastases market share @ Leptomeningeal Metastases Medications

 

Scope of the Leptomeningeal Metastases Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain) and the United Kingdom, and Japan]

  • Key Leptomeningeal Metastases Companies: Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca, and others

  • Key Leptomeningeal Metastases Therapies: 177Lu-DTPA-O Mburtamab Radioimmunotherapy, Rhenium-186 NanoLiposome, ANG1005, and others

  • Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies

  • Leptomeningeal Metastases Market Dynamics:  Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Leptomeningeal Metastases Unmet Needs, KOL’s views, Analyst’s views, Leptomeningeal Metastases Market Access and Reimbursement 

 

To know more about Leptomeningeal Metastases treatment, visit @ Leptomeningeal Metastases Treatment Landscape 

 

Table of Contents 

1. Leptomeningeal Metastases Market Report Introduction

2. Executive Summary for Leptomeningeal Metastases

3. SWOT analysis of Leptomeningeal Metastases

4. Leptomeningeal Metastases Patient Share (%) Overview at a Glance

5. Leptomeningeal Metastases Market Overview at a Glance

6. Leptomeningeal Metastases Disease Background and Overview

7. Leptomeningeal Metastases Epidemiology and Patient Population

8. Country-Specific Patient Population of Leptomeningeal Metastases 

9. Leptomeningeal Metastases Current Treatment and Medical Practices

10. Leptomeningeal Metastases Unmet Needs

11. Leptomeningeal Metastases Emerging Therapies

12. Leptomeningeal Metastases Market Outlook

13. Country-Wise Leptomeningeal Metastases Market Analysis (2020–2034)

14. Leptomeningeal Metastases Market Access and Reimbursement of Therapies

15. Leptomeningeal Metastases Market Drivers

16. Leptomeningeal Metastases Market Barriers

17.  Leptomeningeal Metastases Appendix

18. Leptomeningeal Metastases Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/